MCID: DYS014
MIFTS: 54

Dyspepsia

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyspepsia

MalaCards integrated aliases for Dyspepsia:

Name: Dyspepsia 12 44 15
Indigestion 12 43
Dyspepsia, Indigestion 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2321
ICD10 33 K30 R10.13
MeSH 44 D004415
NCIt 50 C26756
UMLS 73 C0013395

Summaries for Dyspepsia

MedlinePlus : 43 Nearly everyone has had indigestion at one time. It's a feeling of discomfort or a burning feeling in your upper abdomen. You may have heartburn or belch and feel bloated. You may also feel nauseated, or even throw up. You might get indigestion from eating too much or too fast, eating high-fat foods, or eating when you're stressed. Smoking, drinking too much alcohol, using some medicines, being tired, and having ongoing stress can also cause indigestion or make it worse. Sometimes the cause is a problem with the digestive tract, like an ulcer or GERD. Avoiding foods and situations that seem to cause it may help. Because indigestion can be a sign of a more serious problem, see your health care provider if it lasts for more than two weeks or if you have severe pain or other symptoms. Your health care provider may use x-rays, lab tests, and an upper endoscopy to diagnose the cause. You may need medicines to treat the symptoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Dyspepsia, also known as indigestion, is related to gastroparesis and irritable bowel syndrome. An important gene associated with Dyspepsia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Esomeprazole and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Indigestion, also known as dyspepsia, is a condition of impaired digestion. Symptoms may include upper... more...

Related Diseases for Dyspepsia

Diseases related to Dyspepsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Related Disease Score Top Affiliating Genes
1 gastroparesis 31.2 CCK GHRL HTR3A
2 irritable bowel syndrome 30.9 CCK HTR3A SLC6A4 TRPV1
3 bile reflux 30.4 CCK PTGS2
4 eating disorder 30.4 CCK GHRL SLC6A4
5 duodenogastric reflux 30.1 CCK SST
6 depression 30.1 GNB3 HTR1A HTR3A SLC6A4
7 anxiety 30.0 CCK HTR1A HTR3A SLC6A4
8 gallbladder disease 29.9 CCK CCKAR SST
9 diarrhea 29.9 CCK HTR3A SST
10 constipation 29.7 CCK HTR3A SLC6A4 SST
11 disease of mental health 29.2 CCK HTR1A SLC6A4 TRPV1
12 peptic ulcer disease 29.1 CXCL8 CYP2C19 GHRL HRH2 PTGS2
13 gastritis 28.8 CXCL8 GHRL HRH2 PGC PTGS2
14 duodenal ulcer 28.7 CCK CXCL8 CYP2C19 HRH2 SST
15 major depressive disorder 28.6 CYP2C19 GNB3 HTR1A HTR3A SLC6A4
16 atrophic gastritis 28.6 CXCL8 GHRL PGC SST
17 esophagitis 28.6 CXCL8 CYP2C19 HRH2 PTGS2 TRPV1
18 schizophrenia 27.6 CCK CCKAR GNB3 HRH2 HTR1A HTR3A
19 gastric ulcer 27.2 CXCL8 CYP2C19 HRH2 PTGS1 PTGS2
20 gastroesophageal reflux 26.6 CCK CXCL8 CYP2C19 GHRL HRH2 PTGS1
21 opisthorchiasis 11.0
22 pylorospasm 10.6 GHRL SST
23 opioid abuse 10.5 CCK CCKAR
24 trigeminal neuralgia 10.5 SLC6A4 TRPV1
25 duodenitis 10.4
26 anorexia nervosa 10.4 CCK GHRL SLC6A4
27 postcholecystectomy syndrome 10.4 CCK SST
28 rumination disorder 10.4 HTR1A HTR3A
29 psychosexual disorder 10.4 HTR1A SLC6A4
30 chronic laryngitis 10.3 CYP2C19 HRH2
31 helicobacter pylori infection 10.3
32 pain agnosia 10.3 CCK PTGS2 TRPV1
33 agnosia 10.3 CCK PTGS2 TRPV1
34 pancreatic steatorrhea 10.3 CCK GHRL
35 phobic disorder 10.3 HTR1A SLC6A4
36 bulimia nervosa 10.3 CCK GHRL HTR3A SLC6A4
37 motion sickness 10.2 HTR1A HTR3A
38 glucose metabolism disease 10.2 GHRL SST TRPV1
39 periodic limb movement disorder 10.2 HTR1A SLC6A4
40 acquired metabolic disease 10.2 GHRL SST TRPV1
41 premature ejaculation 10.2 HTR1A HTR3A SLC6A4
42 specific developmental disorder 10.2 CCK GHRL SLC6A4 TRPV1
43 brunner syndrome 10.2 HTR1A HTR3A SLC6A4
44 pancreas disease 10.2 CCK SST TRPV1
45 generalized anxiety disorder 10.2 HTR1A HTR3A SLC6A4
46 pancreatic cholera 10.2 CCK HRH2 SST
47 acute generalized exanthematous pustulosis 10.2 CXCL8 PTGS2
48 duodenal gastrinoma 10.2 CCK SST
49 leukoregulin 10.2 CXCL8 PTGS2
50 cholelithiasis 10.1 CCK CCKAR SST

Graphical network of the top 20 diseases related to Dyspepsia:



Diseases related to Dyspepsia

Symptoms & Phenotypes for Dyspepsia

GenomeRNAi Phenotypes related to Dyspepsia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.4 HRH2 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.4 HRH2 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.4 HRH2 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Dyspepsia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 TRPV1 HTR1A HTR3A CCK PTGS1 CCKAR
2 homeostasis/metabolism MP:0005376 9.9 HRH2 SST TRPV1 HTR1A HTR3A CCK
3 endocrine/exocrine gland MP:0005379 9.86 HRH2 HTR3A CCK PTGS1 CCKAR PTGS2
4 digestive/alimentary MP:0005381 9.8 SST HRH2 PTGS1 CCKAR PTGS2 GHRL
5 nervous system MP:0003631 9.7 TRPV1 HTR1A HTR3A CCK PTGS1 CCKAR
6 renal/urinary system MP:0005367 9.1 TRPV1 HTR3A CCK PTGS1 CCKAR PTGS2

Drugs & Therapeutics for Dyspepsia

Drugs for Dyspepsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 452)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 161796-78-7, 119141-88-7 4594 9579578
2
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 75614-87-8, 51-45-6 774
3
Mianserin Approved, Investigational Phase 4 24219-97-4 4184
4
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
6
Famotidine Approved Phase 4,Phase 3 76824-35-6 3325
7
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Not Applicable 102625-70-7 4679
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
9
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
10
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
11
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
12
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
13
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
14
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22204-53-1 1302 156391
15
Metronidazole Approved Phase 4,Phase 3,Not Applicable 443-48-1 4173
16
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
17
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Not Applicable 50-48-6 2160
18
Cyclobenzaprine Approved Phase 4 303-53-7 2895
19
Dopamine Approved Phase 4,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
20
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
21
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
22
Ranitidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 66357-59-3, 66357-35-5 3001055
23
Tetracycline Approved, Vet_approved Phase 4,Not Applicable 60-54-8 5353990
24
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Not Applicable 21645-51-2
25
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
26 Hydrotalcite Approved, Experimental, Investigational Phase 4,Not Applicable 12304-65-3
27
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
28
Furazolidone Approved, Investigational, Vet_approved Phase 4 67-45-8 3435 5323714
29
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
30
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
31
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
32
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 447043
33
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2 114-07-8 12560
34
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
35
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
36
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
37
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
38
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
39
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3 624-49-7 5271565 637568
40
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
41
Ibuprofen Approved Phase 4,Phase 3,Phase 2 15687-27-1 3672
42
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
43
Pancrelipase Approved, Investigational Phase 4,Phase 3 53608-75-6
44
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
45
Tinidazole Approved, Investigational Phase 4,Phase 2,Phase 3 19387-91-8 5479
46
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
47
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
48
Racepinephrine Approved Phase 4 329-65-7 838
49
Loperamide Approved Phase 4,Phase 2,Phase 3 53179-11-6 3955
50
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476

Interventional clinical trials:

(show top 50) (show all 416)
# Name Status NCT ID Phase Drugs
1 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
2 Mirtazapine Versus Placebo in Functional Dyspepsia Unknown status NCT01240096 Phase 4 Mirtazapine
3 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
4 The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia Unknown status NCT01608750 Phase 4 Pantoprazol;Folic Acid
5 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
6 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
7 Mast Cells in Acid-induced Intestinal Permeability Unknown status NCT02664051 Phase 4 Nalcrom;placebo
8 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
9 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
10 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
11 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
12 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
13 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
14 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
15 Buspirone Plus Omeprazole for Functional Dyspepsia Completed NCT03444831 Phase 4 Buspirone;Placebo Oral Tablet
16 Comparison of Pantoprazole and Ranitidine in Dyspepsia Completed NCT01737840 Phase 4 Pantoprazole;Ranitidine
17 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia Completed NCT02037776 Phase 4 Rikkunshito;Rikkunshito placebo
18 Efficacy of Banhasasim-tang on Functional Dyspepsia Completed NCT00987805 Phase 4
19 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia Completed NCT01851863 Phase 4 Omeprazole;Flupentixol-Melitracen(psychological and GI) + Omeprazole;Flupentixol-Melitracen(psychological) + Omeprazole;Flupentixol-Melitracen(without explanation) + Omeprazole
20 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
21 A Study to Demonstrate the Efficacy and Safety of Motilitone® Completed NCT01817465 Phase 4 Motilitone ®;Pantoline®;Motilitone® and Pantoline®
22 The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study Completed NCT02460601 Phase 4 Qizhiweitong granule
23 A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain Completed NCT02197143 Phase 4 esomeprazole;Ranitidine;hydrotalcid
24 High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
25 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
26 Proton Pump Inhibitor Treatment Stop Completed NCT00120315 Phase 4 esomeprazole
27 Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
28 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
29 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
30 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole Completed NCT01281501 Phase 4 Normal saline;Pantoprazole;Oral antacid;Hyoscine butylbromide
31 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
32 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
33 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
34 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
35 Ulcer Prevention Study in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
36 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit Completed NCT00844831 Phase 4 Lubiprostone
37 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
38 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
39 Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis Completed NCT02068482 Phase 4 Rifaximin
40 Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance Completed NCT00400400 Phase 4 Enteric-coated mycophenolate sodium (EC-MPS);Mycophenolate mofetil;Placebo to mycophenolate sodium;Placebo to mycophenolate mofetil
41 Tecfidera and the Gut Microbiota Completed NCT02471560 Phase 4 dimethyl fumarate;injectable MS DMT
42 Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation Completed NCT00239005 Phase 4 Enteric-Coated Mycophenolate Sodium (EC-MPS);Mycophenolate Mofetil (MMF)
43 Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion Completed NCT00843063 Phase 4 pantoprazole vs famotidine
44 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)
45 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
46 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
47 Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction Completed NCT01258296 Phase 4 Fentanyl;Inactive patch
48 Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients Completed NCT00650455 Phase 4 valdecoxib;naproxen;placebo
49 Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
50 Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. Completed NCT01056822 Phase 4 1;2

Search NIH Clinical Center for Dyspepsia

Cochrane evidence based reviews: dyspepsia

Genetic Tests for Dyspepsia

Anatomical Context for Dyspepsia

MalaCards organs/tissues related to Dyspepsia:

41
Testes, Kidney, Liver, Brain, Small Intestine, Colon, Bone

Publications for Dyspepsia

Articles related to Dyspepsia:

(show top 50) (show all 825)
# Title Authors Year
1
Association of Low Fecal Elastase-1 and Non-Ulcer Dyspepsia. ( 29914168 )
2018
2
Potential risk factors and prevalence of Helicobacter pylori infection among adult patients with dyspepsia symptoms in Cameroon. ( 29907086 )
2018
3
Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. ( 29421792 )
2018
4
Dyspepsia, functional dyspepsia and Rome IV criteria. ( 29900746 )
2018
5
New Medical Approach to Functional Dyspepsia, from Core Symposium 3, Japan Gastroenterological Association 2015-2017. ( 29393229 )
2018
6
Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia. ( 29887600 )
2018
7
Editorial on the article A<Factors associated with uninvestigated dyspepsia in students at four Latin American schools of medicine: A multicenter studyA>. ( 29891132 )
2018
8
Efficacy of narrow-band imaging for detecting intestinal metaplasia in adult patients with symptoms of dyspepsia. ( 29449092 )
2018
9
Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. ( 29392796 )
2018
10
Management of dyspepsia-The role of the emergency department observation unit to optimize patient outcomes. ( 29444751 )
2018
11
Oral Capsaicin Test and Functional Dyspepsia: Any Consideration for Helicobacter pylori Infection and Concomitant Medications? ( 29887603 )
2018
12
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia. ( 29941708 )
2018
13
Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology? ( 29774764 )
2018
14
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial. ( 29938452 )
2018
15
Prevalence and Risk Factors of Functional Dyspepsia in Health Check-up Population: A Nationwide Multicenter Prospective Study. ( 29938463 )
2018
16
Demographic and Clinical Correlates of Mucosal Disaccharidase Deficiencies in Children With Functional Dyspepsia. ( 29762379 )
2018
17
Response to Treatment of <i>Helicobacter pylori</i>-associated Dyspepsia: Eradication of <i>Helicobacter pylori</i> or Correction of Gastric or Intestinal Dysbiosis? ( 29969862 )
2018
18
Burden of impaired sleep quality on work productivity in functional dyspepsia. ( 29774153 )
2018
19
Effect of Zhizhu Kuanzhong capsule on functional dyspepsia: Protocol for a systematic review and meta-analysis of randomized controlled trials. ( 29419664 )
2018
20
Gastric bacterial Flora in patients Harbouring Helicobacter pylori with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy. ( 29373960 )
2018
21
New insights into functional dyspepsia: further evidence for postprandial distress syndrome as a distinct disease. ( 29396033 )
2018
22
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. ( 29411724 )
2018
23
Fat label compared with fat content: gastrointestinal symptoms and brain activity in functional dyspepsia patients and healthy controls. ( 29924294 )
2018
24
Complementary and alternative treatment in functional dyspepsia. ( 29435308 )
2018
25
Abnormal Gastrointestinal Imaging in a Patient with Dyspepsia. ( 29409878 )
2018
26
Sleep disturbance and psychological distress are associated with functional dyspepsia based on Rome III criteria. ( 29776354 )
2018
27
Effect of miRNA-19a on gastrointestinal motility in rats with functional dyspepsia. ( 29805508 )
2018
28
Electroacupuncture via chronically implanted electrodes improves gastric dysmotility mediated by autonomic-cholinergic mechanisms in a rodent model of functional dyspepsia. ( 29856090 )
2018
29
Time trends in dyspepsia and association with H. pylori and work-related stress-An observational study in white collar employees in 1996 and 2015. ( 29933411 )
2018
30
Helicobacter pylori among patients with uninvestigated dyspepsia: issues to be remembered. ( 29384763 )
2018
31
The effect of Helicobacter pylori eradication on functional dyspepsia in Turkish children. ( 29873438 )
2018
32
Role of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift. ( 29791992 )
2018
33
Mechanism of Action of STWA 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target. ( 29421789 )
2018
34
The association between adult-type hypolactasia and symptoms of functional dyspepsia. ( 29384557 )
2018
35
Exploring current status of Helicobacter pylori infection in different age groups of patients with dyspepsia. ( 29368191 )
2018
36
Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. ( 29396034 )
2018
37
Plasma ghrelin level and plasma ghrelin/obestatin ratio are related to intestinal metaplasia in elderly patients with functional dyspepsia. ( 28419119 )
2017
38
Weikangning therapy in functional dyspepsia and the protective role of Nrf2. ( 28928800 )
2017
39
Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol. ( 28951846 )
2017
40
Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia? ( 28818267 )
2017
41
&amp;quot;First Do No Harm&amp;quot;: Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. ( 28932929 )
2017
42
Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. ( 28160607 )
2017
43
Superior Mesenteric Artery Syndrome May Be Overlooked in Women with Functional Dyspepsia. ( 28883239 )
2017
44
Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: A multi-center randomized double-blind placebo-controlled clinical study. ( 28852318 )
2017
45
Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. ( 28854971 )
2017
46
Effectiveness of Quercus brantii hydroalcoholic extract on dyspepsia: A randomized, double blind clinical trial. ( 28852653 )
2017
47
Exhaled nitric oxide as a potential marker for detecting non-ulcer dyspepsia and peptic ulcer disease. ( 28947681 )
2017
48
Acupuncture and related therapies used as add-on or alternative to prokinetics for functional dyspepsia: overview of systematic reviews and network meta-analysis. ( 28871092 )
2017
49
Editorial: Moving Away From Focussing on Gastric Pathophysiology in Functional Dyspepsia: New Insights and Therapeutic Implications. ( 28050031 )
2017
50
Food and functional dyspepsia: a systematic review. ( 28913843 )
2017

Variations for Dyspepsia

Expression for Dyspepsia

Search GEO for disease gene expression data for Dyspepsia.

Pathways for Dyspepsia

Pathways related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 CCK CCKAR CXCL8 GHRL GNB3 HRH2
2 12.27 GNB3 HTR1A PTGS1 PTGS2
3
Show member pathways
12.03 CXCL8 GNB3 PTGS2
4
Show member pathways
11.91 CYP2C19 PTGS1 PTGS2
5
Show member pathways
11.74 GNB3 HTR1A HTR3A
6
Show member pathways
11.7 CYP2C19 PTGS1 PTGS2
7 11.65 CXCL8 GNB3 HTR1A HTR3A SLC6A4 SST
8 11.25 CYP2C19 GNB3 PTGS1
9 11.22 CYP2C19 GNB3 HTR1A HTR3A PTGS1 PTGS2
10 10.99 PTGS1 PTGS2
11
Show member pathways
10.97 PTGS1 PTGS2
12 10.94 HTR1A HTR3A SLC6A4
13 10.89 PTGS1 PTGS2
14 10.86 PTGS1 PTGS2
15 10.61 CXCL8 PTGS1 PTGS2
16 10.58 PTGS1 PTGS2

GO Terms for Dyspepsia

Cellular components related to Dyspepsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.56 CCK GNB3 HTR1A TRPV1
2 neuronal cell body GO:0043025 9.46 CCK HTR3A SST TRPV1
3 organelle membrane GO:0031090 9.13 CYP2C19 PTGS1 PTGS2
4 neuron projection GO:0043005 9.02 GNB3 HTR3A PTGS2 SLC6A4 TRPV1

Biological processes related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.87 CCK CXCL8 GHRL SST
2 inflammatory response GO:0006954 9.83 CXCL8 PTGS1 PTGS2 TRPV1
3 regulation of cell proliferation GO:0042127 9.73 CXCL8 GHRL PTGS1 PTGS2
4 excitatory postsynaptic potential GO:0060079 9.58 GHRL HTR3A TRPV1
5 decidualization GO:0046697 9.55 GHRL PTGS2
6 prostaglandin metabolic process GO:0006693 9.54 PTGS1 PTGS2
7 memory GO:0007613 9.54 HRH2 PTGS2 SLC6A4
8 vasoconstriction GO:0042310 9.51 HTR1A SLC6A4
9 regulation of blood pressure GO:0008217 9.5 GNB3 PTGS1 PTGS2
10 prostaglandin biosynthetic process GO:0001516 9.49 PTGS1 PTGS2
11 cellular response to ATP GO:0071318 9.48 PTGS2 TRPV1
12 cyclooxygenase pathway GO:0019371 9.46 PTGS1 PTGS2
13 response to organonitrogen compound GO:0010243 9.33 PTGS2 SST TRPV1
14 regulation of hormone secretion GO:0046883 9.26 CCKAR HTR1A
15 G-protein coupled receptor signaling pathway GO:0007186 9.23 CCK CCKAR CXCL8 GHRL GNB3 HRH2
16 negative regulation of synaptic transmission, dopaminergic GO:0032227 8.96 PTGS2 SLC6A4
17 signal transduction GO:0007165 10.1 CCK CCKAR CXCL8 GNB3 HRH2 HTR1A

Molecular functions related to Dyspepsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.56 CCKAR GNB3 HRH2 HTR1A
2 heme binding GO:0020037 9.5 CYP2C19 PTGS1 PTGS2
3 peroxidase activity GO:0004601 9.37 PTGS1 PTGS2
4 hormone activity GO:0005179 9.33 CCK GHRL SST
5 serotonin binding GO:0051378 8.96 HTR1A HTR3A
6 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Dyspepsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....